We are international
publications TEXT SIZE   
myeloma today    back

Winter 2004/2005 Volume 6, Issue 3:
The Expanding Role of Proteasome Inhibition in Multiple Myeloma
By Robert Orlowski, MD, PhD
At the 2004 ASH meeting, data from a variety of proteasome inhibitor studies was discussed. Based on these, it seems safe to conclude that more patients with relapsed or refractory disease will benefit from such therapy than previously thought.

Be the first to comment

 related articles